MediWound (NASDAQ:MDWD) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of MediWound (NASDAQ:MDWD) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning.

Other equities analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research report on Friday, July 17th. Finally, Oppenheimer reissued an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $33.00.

MediWound Stock Down 1.3%

NASDAQ:MDWD opened at $13.39 on Friday. MediWound has a 12-month low of $13.29 and a 12-month high of $20.30. The stock’s fifty day simple moving average is $14.33 and its 200-day simple moving average is $15.92. The firm has a market capitalization of $172.06 million, a P/E ratio of -7.44 and a beta of 0.15.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The company had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. As a group, equities research analysts expect that MediWound will post -2.31 earnings per share for the current year.

Insider Buying and Selling

In other MediWound news, Director David Morton Fox acquired 3,537 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average price of $14.11 per share, with a total value of $49,907.07. Following the purchase, the director owned 22,283 shares of the company’s stock, valued at $314,413.13. This represents a 18.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its position in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 481 shares during the period. Russell Investments Group Ltd. grew its position in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares during the period. BNP Paribas Financial Markets grew its position in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares in the last quarter. Finally, Quarry LP bought a new stake in MediWound during the 4th quarter worth approximately $26,000. 46.83% of the stock is owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.